Objective:
To present an update on the PRISM clinical trial for 4D-150 in treating wet AMD, highlighting its potential impact on treatment frequency.
Key Findings:
- Aflibercept expression sustained up to 104 weeks with stable visual acuity and OCT findings.
- 57% of patients were injection-free at 52 weeks; this increased to 80% in recently diagnosed patients.
- Safety profile was promising with only 2.8% experiencing transient adverse effects, and 99% completed steroid taper on time.
Interpretation:
The findings suggest that 4D-150 may reduce the need for frequent anti-VEGF treatments while maintaining safety, potentially improving patient quality of life.
Limitations:
- Early-stage trial results; further validation needed in pivotal Phase 3 trials.
- Limited sample size in the reported cohorts, and long-term safety data is still required.
Conclusion:
4D-150 shows potential as a new treatment option for wet AMD, pending results from ongoing Phase 3 trials, which are crucial for confirming these findings.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
